Shares of bluebird bio Inc (NASDAQ:BLUE) have been assigned a consensus recommendation of “Hold” from the twenty-five analysts that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $191.26.
Several research firms recently commented on BLUE. Maxim Group reissued a “hold” rating and set a $200.00 price target on shares of bluebird bio in a research report on Thursday, February 22nd. Leerink Swann lowered bluebird bio from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $162.00 to $194.00 in a research report on Thursday, January 25th. CIBC began coverage on bluebird bio in a research report on Thursday, December 21st. They set a “market perform” rating on the stock. BidaskClub raised bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 26th. Finally, Oppenheimer began coverage on bluebird bio in a research report on Wednesday, December 20th. They set a “market perform” rating on the stock.
In other bluebird bio news, insider Jason Cole sold 1,129 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $173.38, for a total value of $195,746.02. Following the transaction, the insider now directly owns 19,945 shares of the company’s stock, valued at approximately $3,458,064.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 17,262 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total value of $3,381,798.42. Following the completion of the sale, the chief operating officer now owns 28,512 shares of the company’s stock, valued at $5,585,785.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 182,098 shares of company stock worth $33,999,709. 3.90% of the stock is currently owned by corporate insiders.
bluebird bio (NASDAQ BLUE) traded up $1.10 during midday trading on Wednesday, hitting $233.05. The stock had a trading volume of 383,300 shares, compared to its average volume of 821,761. The firm has a market cap of $11,650.00, a price-to-earnings ratio of -43.27 and a beta of 2.05. bluebird bio has a fifty-two week low of $74.45 and a fifty-two week high of $234.90.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.84). The company had revenue of $4.17 million for the quarter, compared to analyst estimates of $7.11 million. bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The business’s revenue was up 169.0% on a year-over-year basis. During the same period last year, the firm posted ($1.88) earnings per share. research analysts forecast that bluebird bio will post -8.25 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/03/12/bluebird-bio-inc-blue-receives-187-42-consensus-target-price-from-analysts.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.